Skip to content

US · HSCSW · MEDICAL - DEVICES

HeartSciences Inc. (HSCSW) intrinsic value and stock valuation

$0.05as of 2026-09-18 · Mkt cap 133.18K

Data updated · price as of 2026-09-18

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

HeartSciences Inc. DCF and intrinsic value

InvestorsCraft values HSCSW with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from HSCSW’s statements →

HeartSciences Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Medical - Devices Southlake, TX, US heartsciences.com

How the business is doing

Fiscal 2026–2020, USD

Revenue
$64.2B+71.3% 5y CAGRd
20262020
Net income
-$-3.81T
20262020
Free cash flow
-$-3.85T
20262020
Total equity
$315.6B+9% 5y CAGRd
20262020

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2026–2020, USD
FYFYFYFYFY
Revenue$4.32B$4.35B$18.6B$5.15B$14.4B
Operating income-$-8.41T-$-8.35T-$-6.31T-$-6.11T-$-4.71T
Net income-$-9.14T-$-8.77T-$-6.61T-$-6.35T-$-4.83T
EPSd-$-3.48M-$-9.34M-$-18.74M-$-79.92M-$-145.48M
Operating cash flow-$-7.43T-$-7.41T-$-6.07T-$-5.77T-$-3.64T
Capital expenditure-$-44.45B-$-30.19B-$-125.27B-$-18.31B-$-1.93B
Free cash flow-$-7.47T-$-7.44T-$-6.2T-$-5.79T-$-3.65T
Total assets$5,262.7T$4.22T$9.5T$3.29T$2.09T
Total debt$3,936.6T$2.99T$1.04T$1.57T$6.16T
Net debt$2,279.8T$1.89T-$-4.77T-$-94.6B$5.24T
Total equity$225.5T$205.2B$7.32T$230.6B-$-6.06T
Cash and short-term investments$1,656.8T$1.1T$5.81T$1.66T$918.3B
Income statement
FYFYFYFYFY
Revenue$4.32B$4.35B$18.6B$5.15B$14.4B
Cost of revenue$133.1B$129.8B$101.2B$29.7B$34.5B
Gross profit-$-128.8B-$-125.49B-$-82.61B-$-24.56B-$-20.08B
Research and development expenses$2,839T$4.39T$2.88T$2.46T$3T
Selling, general and administrative expenses$5,576.4T$3.84T$3.34T$3.63T$1.69T
Other expenses-$-8,407.13T$0.00$0.00$0.00$0.00
Operating expenses$8.28T$8.23T$6.22T$6.09T$4.69T
Cost and expenses$8.42T$8.36T$6.32T$6.12T$4.72T
Interest income$0.00$87.8B$0.00$0.00$0.00
Interest expense$753B$500.5B$354.1B$243.2B$371.6B
Depreciation and amortization$0.00$128B$95.1B$26.9B$26.6B
Ebitda-$-8.41T-$-8.22T-$-6.16T-$-6.08T-$-4.43T
Operating income-$-8.41T-$-8.35T-$-6.31T-$-6.11T-$-4.71T
Total other income/expenses, net-$-729.01B-$-412.66B-$-299.44B-$-241.33B-$-118.86B
Income before tax-$-9.14T-$-8.77T-$-6.61T-$-6.35T-$-4.83T
Income tax expense$0.00$0.00$0.00$0.00$0.00
Net income-$-9.14T-$-8.77T-$-6.61T-$-6.35T-$-4.83T
Weighted average shares outstanding$2.63T$938.3B$352.5B$79.5B$33.2B
Weighted average diluted shares outstanding$2.63T$938.3B$352.5B$79.5B$33.2B
Balance sheet
FYFYFYFYFY
Cash and short-term investments$1,656.8T$1.1T$5.81T$1.66T$918.3B
Net receivables$0.00$4.35B$0.00$0.00$2.32B
Inventory$655.6T$650.3B$629.2B$676.4B$674.1B
Total current assets$2,582.9T$2.17T$7.35T$2.7T$1.93T
Property, plant and equipment, net$307.4T$435.2B$560B$590.7B$158.6B
Goodwill and intangible assets$2,372.4T$1.62T$1.59T$0.00$0.00
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$2,679.7T$2.05T$2.15T$590.7B$158.6B
Total assets$5,262.7T$4.22T$9.5T$3.29T$2.09T
Accounts payable$318.3T$318.7B$448.2B$631.4B$694.7B
Short-term debt$3,761.1T$2.67T$602.3B$529.5B$1.72T
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$4,861.1T$3.7T$1.75T$1.83T$3.47T
Long-term debt$175.5T$314.5B$434B$1.04T$4.44T
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$175.5T$314.5B$434B$1.22T$4.67T
Capital lease obligations$314.5T$434B$536.3B$565.9B$91B
Total liabilities$5,036.6T$4.02T$2.19T$3.06T$8.15T
Common stock$3.19T$1.12B$677M$101M$3.32B
Retained earnings-$-85,269.51T-$-76.13T-$-67.36T-$-60.76T-$-54.4T
Accumulated other comprehensive income (loss)$0.00$0.00$0.00$0.00$0.00
Total equity$225.5T$205.2B$7.32T$230.6B-$-6.06T
Total investments$0.00$0.00$0.00$0.00$0.00
Total debt$3,936.6T$2.99T$1.04T$1.57T$6.16T
Net debt$2,279.8T$1.89T-$-4.77T-$-94.6B$5.24T
Cash flow statement
FYFYFYFYFY
Net income-$-9.14T-$-8.77T-$-6.61T-$-6.35T-$-4.83T
Depreciation and amortization$131.4B$128B$95.1B$135.5B$26.6B
Stock-based compensation$1.31T$249.9B$405B$248.3B$68.4B
Change in working capital-$-1.08T$517.9B-$-504.36B$65.4B$1.12T
Accounts receivable$4.35B-$-4.35B$0.00$2.32B-$-2.32B
Inventory-$-5.36B-$-21.09B$47.2B-$-2.22B$76.6B
Accounts payable-$-334M-$-129.52B-$-183.19B$37.8B$359B
Net cash provided by operating activities-$-7.43T-$-7.41T-$-6.07T-$-5.77T-$-3.64T
Investments in property, plant and equipment-$-3.55B-$-3.16B-$-64.46B-$-18.31B-$-1.93B
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities-$-44.45B-$-30.19B-$-125.27B-$-18.31B-$-1.93B
Common stock issued$172.8B$1.15T$10.3T$5.62T$0.00
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$8.03T$2.73T$10.3T$6.53T$3.84T
Net change in cash$558.7B-$-4.71T$4.15T$742.2B$194.8B
Cash at end of period$1.66T$1.1T$5.81T$1.66T$918.3B
Operating cash flow-$-7.43T-$-7.41T-$-6.07T-$-5.77T-$-3.64T
Capital expenditure-$-44.45B-$-30.19B-$-125.27B-$-18.31B-$-1.93B
Free cash flow-$-7.47T-$-7.44T-$-6.2T-$-5.79T-$-3.65T
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About HeartSciences Inc.

        Heart Test Laboratories, Inc. is a medical technology enterprise dedicated to the creation of diagnostic instruments for cardiovascular health. The company's primary offering is the MyoVista wavECG, a sophisticated 12-lead resting electrocardiograph. This device provides essential diagnostic insights into cardiac dysfunction, in addition to supplying standard 12-lead resting ECG information. Serving a diverse range of medical environments, its products are adopted by clinics, physicians' offices, urgent care centers, and hospitals. Founded in 2007, the firm's operations are headquartered in Southlake, Texas.

        CEO
        Andrew Simpson
        Employees
        14
        Beta
        1.86

        Explore

        Frequently asked questions

        What is the intrinsic value of HeartSciences Inc. (HSCSW)?

        InvestorsCraft does not currently publish an intrinsic value for HSCSW. How the IC value is calculated.

        Is HSCSW undervalued?

        InvestorsCraft does not publish an undervaluation signal for HSCSW at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Sep 19, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.